Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05441046
Other study ID # Gensci048-ST-I
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date June 7, 2022
Est. completion date March 2025

Study information

Verified date May 2022
Source GeneScience Pharmaceuticals Co., Ltd.
Contact Shuaishuai Zhang, MD
Phone 86 21 6087 1690
Email zhangshuaishuai@gensci-china.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I, multicenter, open-label dose escalation and expansion study to evaluate genakumab alone and in combination with tislelizumab in adult patients with advanced solid malignancies.


Description:

The study is divided into two parts: Part I: Part Ia: Two dose groups are planned, which are genakumab 200 mg, 300 mg. Genakumab is administered subcutaneously once every three weeks. Part Ib: Three dose groups are planned, which are genakumab 100 mg plus tislelizumab 200 mg, genakumab 200 mg plus tislelizumab 200 mg, genakumab 300 mg plus tislelizumab 200 mg. Genakumab is administered subcutaneously once every three weeks. Tislelizumab is administered intravenously following genakumab on D1 of every cycle. The study process of Part I includes the screening period (4 weeks), the observation period of dose-limiting toxicity (DLT) evaluation (defined as 3 weeks after first dosing), continuous dosing period (dosing once every 3 weeks until the discontinuation criteria are met), safety follow-up period after discontinuation (28±5 days after last dosing) and progression-free survival follow-up period after discontinuation (once every 6 weeks, until the progression-free survival follow-up endpoint). Part II: The sponsor and the investigator will choose one dose level as RP2D based on the totality of safety, PK, PD, and preliminary efficacy data from Part I. Additional 90 patients (30 patients for each cohort) will be treated at this dose level. The administration method is the same as that in Part I while without DLT observation.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date March 2025
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: Patients may be enrolled in the study only if they meet all of the following inclusion criteria: 1. Patients with advanced malignant tumors by histopathological diagnosis who do not have any acceptable standard treatments currently. Tumor types are specified as follows: Part I (Dose escalation): malignant solid tumors. Part II (Dose expansion): Cohort A: malignant solid tumors (excluding colorectal cancer and pancreatic cancer). Cohort B: colorectal cancer. Cohort C: pancreatic cancer. 2. Patients who have provided informed consent prior to initiation of any study-specific activities/procedures. 3. Age 18-75 years old. 4. Life expectancy = 12 weeks. 5. Solid tumor with = 1 measurable lesion that can be used to measure response according to RECIST v1.1. Index lesions must not be chosen from previously irradiated field unless there has been demonstrated disease progression in that lesion. 6. Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 7. Adequate organ function defined as follow: - Hematological (without need for hematopoietic growth factor or transfusion support within 14 days prior to screening) Absolute neutrophil count (ANC) = 1.5 x 109/L Platelet count (PLT) = 75 x 109/L Hemoglobin (HGB) = 90 g/L - Hepatic Serum total bilirubin = 1.5 x upper limit of normal (ULN) OR = 3 x ULN for patients with liver metastases or Gilbert syndrome Aspartate aminotransferase (AST) = 2.5 x ULN OR = 5 x ULN for patients with liver metastases Alanine aminotransferase (ALT) = 2.5 x ULN OR = 5 x ULN for patients with liver metastases - Renal Serum creatinine = 1.5 x ULN OR creatinine clearance = 45 mL/min (according to the Cockcroft-Gault equation) - Coagulation Activated thromboplastin time (aPTT) = 1.5 x ULN International normalization ratio (INR) = 1.5 x ULN If the patient is receiving anticoagulant therapy, the aPTT or INR must be in the therapeutic range of intended use of anticoagulants. 8. Female patients with the possibility of pregnancy: Agree to practice sexual abstinence or use effective methods of contraception from the time of signing the ICF until at least 6 months after the end of dosing. Male patients: Agree to practice abstinence or use effective contraception from the time of signing the ICF until at least 6 months after the end of dosing. Patients who have recovered from the toxic effects of the last treatment (CTCAE = grade 1, except for special circumstances such as "alopecia") before the first dosing. Exclusion Criteria: Patients with any of the following conditions may not be enrolled in the study: 1. Prior treatment with IL-1ß-targeting agents. 2. Patients with previous severe allergic reactions to any investigational drugs or its components in this trial. 3. Previous or current other types of malignancy diagnosed within 3 years, except as follows: basal cell or squamous cell skin cancer that has been cured, any type of carcinoma in situ that has been cured. 4. Symptomatic central nervous system metastases. Patients with asymptomatic CNS metastases or patients who are radiologically and neurologically stable = 2 weeks following CNS-directed therapy are eligible. 5. Patients who have received any of the following treatments within 4 weeks or within 5 half-lives prior to the first dosing (whichever is shorter): - Anti-tumor therapy (including chemotherapy, targeted therapy, immunotherapy, tumor artery embolization, and radiotherapy, excluding palliative radiotherapy); - Any biological agents targeting immune system (e.g., TNF blockers, anakinra, rituximab, abatacept or tocilizumab, etc); - Any live vaccines or live attenuated vaccines; - Any other investigational drugs or another interventional clinical study (except for the following: patients who participate in an observational, non-interventional clinical study, or are in the follow-up period of an interventional clinical study). 6. Major surgery or severe trauma within 4 weeks prior to the first dosing. Wounds and injuries must be fully recovered. Note: Video-assisted thoracoscopic surgery (VATS) and mediastinoscopy are not considered as major surgery. Patients who have received VATS or mediastinoscopy more than 2 weeks prior to the first dosing may be enrolled at the discretion of the investigator. 7. Patients who have a cardiovascular clinical condition or symptom including: - Unstable angina or myocardial infarction in the past 6 months; - Coronary artery bypass grafting (CABG) in the past 6 months; - Congestive heart failure (NYHA class 2); - Clinically significant malignant arrhythmia (e.g., persistent ventricular tachycardia, clinically significant second- or third-degree atrioventricular block without a pacemaker). 8. Uncontrolled diabetes or hypertension defined by the investigator. 9. History of interstitial lung disease. 10. Active or recurrent liver disease, including hepatitis B, hepatitis C, and liver cirrhosis. 11. Patients with active pulmonary tuberculosis found by medical history or CT examination, or with a history of active pulmonary tuberculosis infection before enrollment (Patients who have received anti-tuberculosis treatment and further examinations confirm that there is no evidence of active infection are eligible.). 12. Patients with active infection requiring systematic treatment within 2 weeks prior to the first dosing (Patients with skin infection requiring only topical treatment are eligible.). 13. Patients with suspected or proven immunocompromised state, including: - Patients with evidence of Human Immunodeficiency Virus (HIV) infection; - Patients requiring systemic or local treatment with any immune modulating agent in doses with systemic effects e.g., high dose oral or intravenous steroids (> 10 mg/d prednisone or its equivalents) or high dose methotrexate (> 15 mg weekly). Topical, inhaled, local steroid use in doses that are not considered to cause systemic effects are permitted. - Patients with active or recurrent autoimmune disease, excluding: hypothyroidism with replacement therapy, skin disease without need for systemic treatment; - Patients with history of allogenic hematopoietic stem cell transplantation or organ transplantation (except corneal transplantation); - Patients with any other medical condition which in the opinion of the investigator places the patients at unacceptable risk for participation in immunomodulatory therapy. Female patients who are pregnant or lactating, or have a positive pregnancy test result at baseline.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Genakumab
genakumab plus tislelizumab 200 mg

Locations

Country Name City State
China Zhejiang Cancer Hospital Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
GeneScience Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary dose-limiting toxicities (DLTs) First cycle (21 days after first dose)
Primary adverse events (AEs) adverse events (AEs) through study completion, an average of 6 months
Primary serious adverse events (SAEs) through study completion, an average of 6 months
Primary PK parameters of genakumab: bioavailability Cycle 1 day 1/day 2/day 3/day 4/day 6/day 8/day 15, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1/day 2/day 3/day 4/day 6/day 8/day 15, and day 1 of every following cycles (every cycle is 21 days) through study completion, an average of 6 months
Primary PK parameters of genakumab: peak concentration (Cmax) Cycle 1 day 1/day 2/day 3/day 4/day 6/day 8/day 15, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1/day 2/day 3/day 4/day 6/day 8/day 15, and day 1 of every following cycles (every cycle is 21 days) through study completion, an average of 6 months
Primary PK parameters of genakumab: area under time-concentration curve (AUC) Cycle 1 day 1/day 2/day 3/day 4/day 6/day 8/day 15, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1/day 2/day 3/day 4/day 6/day 8/day 15, and day 1 of every following cycles (every cycle is 21 days) through study completion, an average of 6 months
Primary PK parameters of genakumab: t1/2 Cycle 1 day 1/day 2/day 3/day 4/day 6/day 8/day 15, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1/day 2/day 3/day 4/day 6/day 8/day 15, and day 1 of every following cycles (every cycle is 21 days) through study completion, an average of 6 months
Primary PK parameters of genakumab: steady-state peak concentration Cycle 1 day 1/day 2/day 3/day 4/day 6/day 8/day 15, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1/day 2/day 3/day 4/day 6/day 8/day 15, and day 1 of every following cycles (every cycle is 21 days) through study completion, an average of 6 months
Primary PK parameters of genakumab: steady-state trough concentration Cycle 1 day 1/day 2/day 3/day 4/day 6/day 8/day 15, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1/day 2/day 3/day 4/day 6/day 8/day 15, and day 1 of every following cycles (every cycle is 21 days) through study completion, an average of 6 months
Primary PK parameters of genakumab: accumulation ratio Cycle 1 day 1/day 2/day 3/day 4/day 6/day 8/day 15, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1/day 2/day 3/day 4/day 6/day 8/day 15, and day 1 of every following cycles (every cycle is 21 days) through study completion, an average of 6 months
Secondary Pharmacodynamic: hsCRP Cycle 1 day 1/day 2/day 3/day 4/day 6/day 8/day 15, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1/day 2/day 3/day 4/day 6/day 8/day 15, and day 1 of every following cycles (every cycle is 21 days) through study completion, an average of 6 months
Secondary Pharmacodynamic: total IL-1ß Cycle 1 day 1/day 2/day 3/day 4/day 6/day 8/day 15, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1/day 2/day 3/day 4/day 6/day 8/day 15, and day 1 of every following cycles (every cycle is 21 days) through study completion, an average of 6 months
Secondary Pharmacodynamic: free IL-1ß Cycle 1 day 1/day 2/day 3/day 4/day 6/day 8/day 15, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1/day 2/day 3/day 4/day 6/day 8/day 15, and day 1 of every following cycles (every cycle is 21 days) through study completion, an average of 6 months
Secondary Pharmacodynamic: IL-6 Cycle 1 day 1/day 2/day 3/day 4/day 6/day 8/day 15, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1/day 2/day 3/day 4/day 6/day 8/day 15, and day 1 of every following cycles (every cycle is 21 days) through study completion, an average of 6 months
Secondary Pharmacodynamic: IL-8 Cycle 1 day 1/day 2/day 3/day 4/day 6/day 8/day 15, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1/day 2/day 3/day 4/day 6/day 8/day 15, and day 1 of every following cycles (every cycle is 21 days) through study completion, an average of 6 months
Secondary Pharmacodynamic: TNF-a. Cycle 1 day 1/day 2/day 3/day 4/day 6/day 8/day 15, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1/day 2/day 3/day 4/day 6/day 8/day 15, and day 1 of every following cycles (every cycle is 21 days) through study completion, an average of 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05539677 - Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Completed NCT05594147 - An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
Not yet recruiting NCT06082557 - A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients Phase 1/Phase 2
Not yet recruiting NCT05508620 - A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors Phase 1
Completed NCT02902237 - tTF-NGR Phase I Study Phase 1
Completed NCT03205176 - AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas Phase 1
Completed NCT01765790 - Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors Phase 1
Completed NCT05930457 - Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors Phase 1
Active, not recruiting NCT01694472 - Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors Phase 1
Completed NCT01391533 - Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors Phase 1
Completed NCT00516438 - Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan Phase 1
Completed NCT01519817 - Cancer Vaccine Targeting Brachyury Protein in Tumors Phase 1
Recruiting NCT03739827 - Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Recruiting NCT05579275 - Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors Early Phase 1
Completed NCT05814835 - First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors Phase 1
Recruiting NCT02421380 - Characterization of Hyperpolarized Pyruvate MRI Reproducibility N/A
Completed NCT02805166 - PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Phase 4